Skip to content
OpenCapital
Get started

Charles River Laboratories CRL Equity method investments (Note 11)

Equity method investments (Note 11) at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——
IQVIA logo
IQVIAIQV
——
Quest Diagnostics logo
Quest DiagnosticsDGX
——
Abbott logo
AbbottABT
——

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-4.6%—
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%—
Debt / equity1×+0.1×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:EquityMethodInvestments.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's equity method investments (note 11).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's equity method investments (note 11)?
Charles River Laboratories (CRL) reported equity method investments (note 11) of $209.72M in Q1 2026.
How has Charles River Laboratories's equity method investments (note 11) changed year-over-year?
Charles River Laboratories's equity method investments (note 11) decreased by 2.0% year-over-year, from $214.03M to $209.72M.
What is the long-term trend for Charles River Laboratories's equity method investments (note 11)?
Over 4 years (2021 to 2025), Charles River Laboratories's equity method investments (note 11) has grown at a 0.7% compound annual growth rate (CAGR), from $201.35M to $206.97M.